R & D

Bristol Myers Squibb Receives European Commission Approval for LAG-3-Blocking Antibody Combination, Opdualag (nivolumab and relatlimab), for the Treatment of Unresectable or Metastatic Melanoma with Tumor Cell PD-L1 Expression < 1%

 This material is intended to notify the press release issued on September 16 (local time) by Bristol Myers Squibb, our license partner for Opdivo.
 Please click for the original press release.